inhibitor (rituximab), IL-6R inhibitors (tocilizumab and sarilumab) and biosimilar (bs) DMARDs)] and targeted synthetic (ts) DMARDs [JAK inhibitors (such as tofacitinib, baricitinib and upadacitinib)] ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

The division will have responsibility for Sanofi's underperforming cancer R&D unit that was revamped earlier this year, as well as key immunology candidates including arthritis therapy sarilumab ...

Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ago ...

IL-6 is considered a suitable target for the treatment of refractory AOSD. Two IL-6 inhibitors, tocilizumab and sarilumab, have been investigated in this setting in varying degrees. Tocilizumab has ...

Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Understanding the risks of different therapeutic options is essential for making treatment decisions ...

and Sanofi’s Kevzara (sarilumab) – are approved for rheumatoid arthritis and other inflammatory conditions. There are no approved therapies in the US to prevent cardiovascular complications in ...